Pfizer-BioNTech Begin Studies on Omicron-Based COVID-19 Vaccines
The companies said the vaccines will be examined in adults 18-55 years old.
Related Articles
Clinicians Often Prefer Older, Generic Antibiotics Over Newer Ones for Gram-Negative Infections
A study finds that despite the development of some new agents for highly-resistant pathogens, prescribers are reluctant to utilize these therapies.
Undernutrition is a Concerning Risk Factor for Tuberculosis in India
Insights from Pranay Sinna MD on a multicenter prospective cohort study on household contacts.
The R21/Matrix-M Vaccine: A Breakthrough in Malaria Eradication Efforts
In a collaboration between the University of Oxford, the Ministry of Health in Rwanda, and the Rwanda Biomedical Centre, groundbreaking data on the R21/Matrix-M malaria…
PEN-FAST Forward: Accelerating Penicillin Allergy De-Labeling
PEN-FAST is a validated risk stratification tool that promotes efficient, safe, and effective de-labeling of penicillin allergies.
FDA Approves Antibiotic for Uncomplicated UTIs
Pivmecillinam (Pivya) was given the nod from the federal agency, and is indicated for female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible…
World Malaria Day: Addressing Challenges and Advances in Malaria Research
Photini Sinnis MD, professor at the Johns Hopkins School of Public Health and Deputy Director of the Johns Hopkins Malaria Research Institute, offers her insights…
Role of Memory B Cells in Protection Against Hepatitis C Reinfections
Study from the Journal of Hepatology aims to characterize immune responses associated with rapid natural clearance of HCV reinfection.
FDA Approves Antibiotic for Uncomplicated UTIs
Pivmecillinam (Pivya) was given the nod from the federal agency, and is indicated for female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible…
Foodborne Disease Outbreaks: 2024 Year-to-Date Insights
FDA recalls, allergy alerts, e coli & salmonella outbreaks, and more.
European Commission Approves Pfizer’s Antibiotic Combination for Multidrug Infections
With this approval, aztreonam-avibactam becomes the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union for treating multidrug-resistant infections, including metallo-β-lactamase-producing bacteria.